Press Releases

March 12, 2014

Aquinox Pharmaceuticals Announces Closing of Initial Public Offering

March 7, 2014

Aquinox Pharmaceuticals Prices Initial Public Offering

December 17, 2013

Aquinox Pharmaceuticals commences Phase 2 clinical trial of AQX-1125 in Chronic Obstructive Pulmonary Disease

July 23, 2013

Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis

April 3, 2013

Aquinox Pharmaceuticals Completes US $18 Million Series C Financing

November 10, 2011

Aquinox Pharmaceuticals Initiates Two Phase IIa Clinical Studies in Airway Inflammation Following Successful Phase I

January 5, 2011

Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound

September 15, 2010

Aquinox Pharmaceuticals appoints Csaba Szabó, M.D., Ph.D., Vice President, Research and Chief Scientific Officer

June 17, 2010

Aquinox Pharmaceuticals Completes US $25 Million Series B Financing

October 11, 2009

Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate

July 10, 2008

Aquinox Pharmaceuticals Inc. Names Board Member

September 14, 2007

With help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia

June 12, 2007

Aquinox Pharmaceuticals Inc. Completes US$14.5 million Series A financing